Single Dose Study of MK-2060 in Healthy Japanese Participants

A Single-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2060 in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220658

Enrollment

Registered

2023-02-23

Start date

2023-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of thrombotic vascular events

Interventions

Single intravenous dose of MK-2060 8, 20 or 50 mg or matching placebo will be administerd. Or, single subctaneous dose of MK-2060 30 mg or matching placebo will be administerd.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy male or female aged 18 to 50 years old with BMI 18 to 32 kg/m2

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Adverse Events	—

Secondary

Measure	Time frame
Following PK parameters and aPTT (activated partial thromboplastin time) Intraveneous administration: AUC0-inf, AUC0-last, AUC0-168, Cmax, C168, Tmax, Tlast, t1/2, CL and Vz Subctaneous administration: AUC0-inf, AUC0-last, AUC0-168, Cmax, C168, Tmax, Tlast, t1/2, CL/F and Vz/F	—

Contacts

Public Contactinquiry mailbox MSDJRCT

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026